Popular search terms:
Search Results
66 results found-
Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.
https://www.seqirus.us/expertise/influenza/pandemic-response-solutions -
Renewal reaffirms longstanding, public-private partnership between Seqirus and the Biomedical Advanced Research and Development Authority (BARDA)
https://www.seqirus.us/news/seqirus-and-us-gov-renew-multi-year-agreement-for-influenza-pandemic-preparedness-and-response -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.us/news -
Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives
https://www.seqirus.us/news/seqirus-awarded-us-government-contract-for-two-influenza-vaccines -
Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.
https://www.seqirus.us/expertise -
The FDA has granted approval of multi-dose vial presentation for AUDENZ™ to help protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic.
https://www.seqirus.us/news/fda-approves-multi-dose-vial-presentation-for-audenz -
New facility in Waltham, Massachusetts, will support CSL’s growing R&D portfolio, including the self-amplifying mRNA technology platform.
https://www.seqirus.us/news/seqirus-announces-new-facility-supporting-research-and-development-of-influenza-vaccine-technology -
Seqirus appoints Roberta Duncan as new program lead to drive technology advancement. Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza.
https://www.seqirus.us/news/seqirus-invests-in-self-amplifying-messenger-rna-technology -
With FDA approval, FLUCELVAX QUADRIVALENT, the first and only cell-based influenza vaccine in the U.S., is now indicated for everyone eligible to receive an influenza vaccine in the United States.
https://www.seqirus.us/news/seqirus-receives-fda-approval-for-flucelvax-quadrivalent-for-children-6-months-and-older -
Seqirus Presents New Data at ESWI 2020 Demonstrating Safety and Immunogenicity of Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine
https://www.seqirus.us/news/seqirus-presents-new-data-at-eswi-2020-demonstrating-safety-and-immunogenicity